Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Exposure of Topical CEE321 in Healthy and Atopic Dermatitis Subjects
NCT04612062Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of CEE321 in atopic dermatitis (AD) (2 arms), sponsored by Novartis. Primary endpoint: Number of subjects with adverse events. Started Feb 2020; status: completed.
02
Drugs
CEE321
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04612062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612062.